Dr. Kraus is board-certified physician (ID and IM) with more than 15 years’ experience in drug development, from Discovery (Tuberculosis Research Section, NIH), to submission (Chief Medical Officer, Nanotherapeutics) to Regulatory review (Medical Officer, Office of Antiinfective Products, FDA). He has also served on the IDSA’s Antibiotic Resistance Committee. Dr. Kraus has contributed to multiple INDs, BLAs and NDAs in infectious disease.

Dr. Snow is a biologic chemist with more than 25 years’ experience in biochemistry, quality and regulatory affairs. She has advised and led the development of innovative regulatory strategies for programs including combination products (drug/device) and the FDA Animal Rule. Dr. Snow has successfully developed regulatory approval strategies for US and global markets, contributing to more 20 IND, 2 BLA, and 3 NDA-related regulatory applications.

Dr. House is a parasitologist with more than 25 years’ experience in biopharmaceutical preclinical research, including basic and applied research in immunology, cytokine biology, immunotoxicology and animal disease modeling. He has evaluated the preclinical safety and efficacy of nearly 400 pharmaceutical, environmental and consumer care products and has successfully supported the acquisition of > $1B in non-dilutive government contracts.